A Phase 1, Randomized, Double-blind, Placebo- and Positive-controlled, Parallel Group Study With Nested Crossover Comparison to Assess the Effect of Maridebart Cafraglutide on QT/QTc Intervals in Participants Living With Overweight or Obesity
Latest Information Update: 19 Nov 2025
At a glance
- Drugs Maridebart cafraglutide (Primary) ; Moxifloxacin
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Amgen
Most Recent Events
- 19 Nov 2025 New trial record